Annual accounts receivable:
$6.98B-$541.98M(-7.20%)Summary
- As of today (May 19, 2025), GSK annual accounts receivable is $6.98 billion, with the most recent change of -$541.98 million (-7.20%) on December 31, 2024.
- During the last 3 years, GSK annual accounts receivable has fallen by -$1.45 billion (-17.19%).
- GSK annual accounts receivable is now -36.10% below its all-time high of $10.92 billion, reached on December 31, 2007.
Performance
GSK Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$9.13B+$2.15B(+30.83%)Summary
- As of today (May 19, 2025), GSK quarterly accounts receivable is $9.13 billion, with the most recent change of +$2.15 billion (+30.83%) on March 31, 2025.
- Over the past year, GSK quarterly accounts receivable has increased by +$508.16 million (+5.89%).
- GSK quarterly accounts receivable is now -16.40% below its all-time high of $10.92 billion, reached on December 31, 2007.
Performance
GSK Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
GSK Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.2% | +5.9% |
| 3 y3 years | -17.2% | -16.2% |
| 5 y5 years | -3.0% | -13.4% |
GSK Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -17.2% | +5.8% | -16.2% | +38.4% |
| 5 y | 5-year | -17.2% | +5.8% | -16.2% | +38.4% |
| alltime | all time | -36.1% | +1731.7% | -16.4% | +2296.3% |
GSK Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $9.13B(+30.8%) |
| Dec 2024 | $6.98B(-7.2%) | $6.98B(-29.3%) |
| Sep 2024 | - | $9.88B(+7.6%) |
| Jun 2024 | - | $9.18B(+6.5%) |
| Mar 2024 | - | $8.62B(+14.6%) |
| Dec 2023 | $7.52B(+14.0%) | $7.52B(-27.8%) |
| Sep 2023 | - | $10.42B(+22.0%) |
| Jun 2023 | - | $8.55B(+1.0%) |
| Mar 2023 | - | $8.46B(+28.3%) |
| Dec 2022 | $6.60B(-21.7%) | $6.60B(-21.3%) |
| Sep 2022 | - | $8.38B(+7.1%) |
| Jun 2022 | - | $7.83B(-28.2%) |
| Mar 2022 | - | $10.90B(+29.3%) |
| Dec 2021 | $8.43B(+11.5%) | $8.43B(-18.4%) |
| Sep 2021 | - | $10.33B(+8.2%) |
| Jun 2021 | - | $9.55B(+7.0%) |
| Mar 2021 | - | $8.92B(+18.0%) |
| Dec 2020 | $7.56B(+5.1%) | $7.56B(-25.1%) |
| Sep 2020 | - | $10.10B(+14.5%) |
| Jun 2020 | - | $8.82B(-16.4%) |
| Mar 2020 | - | $10.55B(+46.7%) |
| Dec 2019 | $7.19B(+9.5%) | $7.19B(-28.4%) |
| Sep 2019 | - | $10.05B(+15.3%) |
| Jun 2019 | - | $8.71B(+2.0%) |
| Mar 2019 | - | $8.54B(+30.1%) |
| Dec 2018 | $6.57B(+4.3%) | $6.57B(-30.9%) |
| Sep 2018 | - | $9.50B(+10.8%) |
| Jun 2018 | - | $8.58B(+0.2%) |
| Mar 2018 | - | $8.56B(+35.9%) |
| Dec 2017 | $6.30B(+11.1%) | $6.30B(-27.7%) |
| Sep 2017 | - | $8.72B(+8.1%) |
| Jun 2017 | - | $8.06B(+3.8%) |
| Mar 2017 | - | $7.77B(+37.0%) |
| Dec 2016 | $5.67B(+0.1%) | $5.67B(-38.4%) |
| Sep 2016 | - | $9.20B(+17.0%) |
| Jun 2016 | - | $7.87B(-6.5%) |
| Mar 2016 | - | $8.41B(+48.4%) |
| Dec 2015 | $5.67B(+2.4%) | $5.67B(-36.7%) |
| Sep 2015 | - | $8.95B(+7.1%) |
| Jun 2015 | - | $8.36B(+2.7%) |
| Mar 2015 | - | $8.14B(+47.0%) |
| Dec 2014 | $5.53B(-15.4%) | $5.53B(-32.8%) |
| Sep 2014 | - | $8.24B(-3.3%) |
| Jun 2014 | - | $8.52B(-3.8%) |
| Mar 2014 | - | $8.86B(+35.4%) |
| Dec 2013 | $6.54B(-1.7%) | $6.54B(-22.3%) |
| Sep 2013 | - | $8.42B(-1.2%) |
| Jun 2013 | - | $8.52B(-1.2%) |
| Mar 2013 | - | $8.62B(+29.7%) |
| Dec 2012 | $6.65B | $6.65B(-27.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2012 | - | $9.11B(+6.4%) |
| Jun 2012 | - | $8.56B(-6.7%) |
| Mar 2012 | - | $9.18B(+34.1%) |
| Dec 2011 | $6.84B(-6.2%) | $6.84B(-25.5%) |
| Sep 2011 | - | $9.19B(-2.0%) |
| Jun 2011 | - | $9.38B(-1.9%) |
| Mar 2011 | - | $9.56B(+31.0%) |
| Dec 2010 | $7.30B(-30.5%) | $7.30B(-22.8%) |
| Sep 2010 | - | $9.45B(+5.2%) |
| Jun 2010 | - | $8.99B(-13.1%) |
| Mar 2010 | - | $10.34B(-1.5%) |
| Dec 2009 | $10.50B(+14.4%) | $10.50B(+8.5%) |
| Sep 2009 | - | $9.68B(+9.6%) |
| Jun 2009 | - | $8.83B(+4.0%) |
| Mar 2009 | - | $8.49B(-7.4%) |
| Dec 2008 | $9.18B(-16.0%) | $9.18B(-6.1%) |
| Sep 2008 | - | $9.77B(-9.1%) |
| Jun 2008 | - | $10.74B(+1.9%) |
| Mar 2008 | - | $10.55B(-3.5%) |
| Dec 2007 | $10.92B(+28.1%) | $10.92B(+6.2%) |
| Sep 2007 | - | $10.28B(+1.2%) |
| Jun 2007 | - | $10.16B(+0.8%) |
| Mar 2007 | - | $10.08B(+18.2%) |
| Dec 2006 | $8.53B(+12.5%) | $8.53B(+501.0%) |
| Sep 2006 | - | $1.42B(-84.6%) |
| Jun 2006 | - | $9.22B(+21.6%) |
| Dec 2005 | $7.58B(-11.2%) | $7.58B(+951.1%) |
| Sep 2005 | - | $721.56M(-1.0%) |
| Jun 2005 | - | $728.57M(-7.7%) |
| Mar 2005 | - | $789.60M(-90.8%) |
| Dec 2004 | $8.54B(+28.7%) | $8.54B(+7.3%) |
| Sep 2004 | - | $7.96B(+20.0%) |
| Dec 2003 | $6.63B(+17.1%) | $6.63B(-34.4%) |
| Mar 2003 | - | $10.12B(+78.5%) |
| Dec 2002 | $5.67B(+7.6%) | $5.67B(+7.6%) |
| Dec 2001 | $5.27B(+5.9%) | $5.27B(+5.9%) |
| Dec 2000 | $4.97B(+83.0%) | $4.97B(+83.0%) |
| Dec 1999 | $2.72B(+1.9%) | $2.72B(+1.9%) |
| Dec 1998 | $2.67B(+19.9%) | $2.67B(+19.9%) |
| Dec 1997 | $2.22B(-9.2%) | $2.22B(-9.2%) |
| Dec 1996 | $2.45B(+9.4%) | $2.45B(+75.2%) |
| Dec 1995 | $2.24B(+60.1%) | - |
| Jun 1994 | $1.40B(+1.2%) | $1.40B(+1.2%) |
| Jun 1993 | $1.38B(+1.0%) | $1.38B(+1.0%) |
| Jun 1992 | $1.37B(+28.7%) | $1.37B(+28.7%) |
| Jun 1991 | $1.06B(+15.7%) | $1.06B(+15.7%) |
| Jun 1990 | $918.56M(+42.1%) | $918.56M(+42.1%) |
| Jun 1989 | $646.27M(+10.3%) | $646.27M(+10.3%) |
| Jun 1988 | $586.14M(+22.6%) | $586.14M(+22.6%) |
| Jun 1987 | $478.15M(+25.5%) | $478.15M(+25.5%) |
| Jun 1986 | $381.10M | $381.10M |
FAQ
- What is GSK annual accounts receivable?
- What is the all time high annual accounts receivable for GSK?
- What is GSK annual accounts receivable year-on-year change?
- What is GSK quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for GSK?
- What is GSK quarterly accounts receivable year-on-year change?
What is GSK annual accounts receivable?
The current annual accounts receivable of GSK is $6.98B
What is the all time high annual accounts receivable for GSK?
GSK all-time high annual accounts receivable is $10.92B
What is GSK annual accounts receivable year-on-year change?
Over the past year, GSK annual accounts receivable has changed by -$541.98M (-7.20%)
What is GSK quarterly accounts receivable?
The current quarterly accounts receivable of GSK is $9.13B
What is the all time high quarterly accounts receivable for GSK?
GSK all-time high quarterly accounts receivable is $10.92B
What is GSK quarterly accounts receivable year-on-year change?
Over the past year, GSK quarterly accounts receivable has changed by +$508.16M (+5.89%)